Biohaven Pharmaceutical Holding (BHVN) PT Raised to $48 at Needham & Company; Adding Migraine Prevention Revenue to Model
Tweet Send to a Friend
Needham & Company raised its price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $48.00 (from $36.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
